A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects
Article
[키워드] Administered
Adults
age
antigenic
approved
booster
children
clinical development
comparable
country
CoV
COVID-19 pandemic
COVID-19 severity
disease
Effectiveness
Efficacy
Emergency use
Emergency use authorization
generate
geometric mean titer
group
Healthcare system
Heterologous
heterologous prime and boost vaccines
heterologous prime-boost
immune response
inactivated
Inactivated vaccine
inactivated virus adjuvanted vaccine
increase in
India
induce
Like
memory B
morbidity
Mortality
neutralization
neutralization titer
original antigenic sin
over
pandemic
pediatric
phase
Population
prime and boost
reactogenicity
reduce
reduction in
robust
safety profile
SARS – CoV – 2
SARS-CoV-2 variant
seroconversion rate
symptomatic COVID-19 disease
synergy
T-cell responses
TLR7/8
vaccinated individuals
vaccination
Vaccine
vaccine challenges
Vaccine development
vaccine dose
Vaccines
variants of concern
variants of concern (VOCs)
virus
VOCs
waning immunity
[DOI] 10.3389/fimmu.2022.940715 PMC 바로가기
[DOI] 10.3389/fimmu.2022.940715 PMC 바로가기